Thanks for posting this Mike. It’s such a great article that covers so many of the key issues including the current cost of HepC treatment set by Gilead, the fact that cheaper generics are available, the conflict of interest of key players and the role of government etc.
Good to see the following words printed in this journal:
Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices; rather, prescription drugs are priced…………..primarily on the basis of what the market will bear. Yes!
.
